[Clinical and pharmacoeconomic aspects of the antisecretory therapy of gastroesophageal refluxed disease].
The article discloses the results of an open prospective randomized study of the antisecretory therapy efficiency conducted among 20 patients with gastroesophageal refluxed disease (erosive form, non-complicated course). The selection of the optimal antisecretory drug was substantiated from the point of view of the clinic-diagnostic and pharmacoeconomic assessment of the results of the above-mentioned therapy conducted with the application of rabeprosole (pariet) and its generic omeprosole (omez).